Kalaris Therapeutics Inc
- KLRS
- NASDAQ
- Biotechnology
- Retinal Disease Treatments
- Anti-VEGF Therapies
$1.88
Today −6.00%Quote Oct 19, 2026, 04:59 PM UTC
−36.71%over the last month
Max drawdown −38.4%From 1-month high −38.4%3 months −50.0%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Kalaris Therapeutics
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
20
Market value
$41.1M
Quote Oct 19
Analyst target
$17.00
+804.3% from here
Floor
$1.58
15.8% below price
Resistance
$1.97
4.6% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about KLRSPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free